Linscomb & Williams Inc. Sells 426 Shares of Johnson & Johnson (JNJ)

Linscomb & Williams Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,708 shares of the company’s stock after selling 426 shares during the period. Johnson & Johnson accounts for 0.7% of Linscomb & Williams Inc.’s portfolio, making the stock its 20th largest position. Linscomb & Williams Inc.’s holdings in Johnson & Johnson were worth $8,292,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Goodman Financial Corp purchased a new position in Johnson & Johnson during the 4th quarter worth $104,000. Stelac Advisory Services LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $108,000. Princeton Capital Management LLC purchased a new position in Johnson & Johnson during the 1st quarter worth $141,000. Price Wealth Management Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth $148,000. Finally, Smart Portfolios LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $150,000. 65.97% of the stock is owned by hedge funds and other institutional investors.

Several analysts have weighed in on the company. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 16th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, April 17th. Deutsche Bank reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Stifel Nicolaus dropped their price target on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Wednesday, April 18th. Finally, Leerink Swann reiterated an “outperform” rating and set a $160.00 price target (down previously from $175.00) on shares of Johnson & Johnson in a research note on Wednesday, April 18th. They noted that the move was a valuation call. Six analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $141.60.

NYSE JNJ opened at $125.75 on Friday. The stock has a market capitalization of $335.36 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 1.91 and a beta of 0.74. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The business had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. During the same quarter in the prior year, the firm earned $1.83 earnings per share. The business’s revenue was up 12.6% compared to the same quarter last year. equities research analysts expect that Johnson & Johnson will post 8.13 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were issued a dividend of $0.90 per share. The ex-dividend date was Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.86%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply